Mannkind Corp (MNKD) Stock Price, Quote & News

Company Profile

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of therapeutic products and services for endocrine and orphan lung diseases in the United States. It offers Afrezza Inhalation Powder, an inhaled insulin used to improve glycemic control in adults with diabetes; the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults; and Tyvaso DPI for the treatment of pulmonary arterial hypertension and pul...

Industry: Biotechnology

Sector: Healthcare

Phone: 818 661 5000

Website: www.mannkindcorp.com

Address:

1 Casper Street, Danbury, United States

YolitheDolly Sep. 14 at 1:51 PM

$MNKD Gotta love that moron Clan. He’s a MNKD employee and I called him out for the lies and deception he posts here. He blocks me yet he unblocks me to read my comments and respond. What a chicken sheet.

0 · Reply

clan Sep. 14 at 10:15 AM

$MNKD I'm living rent-free in this habitual whiner's cavenous hollow head. MNKD-26In26

0 · Reply

Lazarus2024 Sep. 14 at 6:17 AM

$MNKD Why would a company keep a CEO that hasn’t improved shareholder value ? A: The company doesn’t care about shareholder value or shareholders. The company only cares about management salaries and bonuses.

2 · Reply

grampslol Sep. 13 at 5:01 PM

$MNKD Yes , they certainly have great difficulty retaining key employees @kevinmik their turnover and problem recruiting is a negative for sure. No company exit strategy exists. No respectable BP has interest in them IMHO

1 · Reply

grampslol Sep. 13 at 4:46 PM

$MNKD Reminder : Scripts for their only drug afrezza dpi approved in 2014 for diabetes were terrible for the week of 9/5/2025 ! Nrx 382 Rrx 471

0 · Reply

grampslol Sep. 13 at 4:42 PM

$MNKD I say No to presenting at EASD next week @kevinmik and Yes to the real possibility uthr will cut mnkd from the sma to save costs especially since lqda Yutrepria dpi is doing so well. JMHHO

0 · Reply

kevinmik Sep. 13 at 3:38 PM

$MNKD Will MNKD be presenting Inhale-1 Study Full 52-Week & Safety Extension Results at next weeks EASD Annual Meeting. If not, which forum will MNKD choose to present the results and when ? The study was completed back in April 2025 and the results should be available by now. The 61st Annual Meeting of the European Association for the Study of Diabetes (EASD) will be held from September 15–19, 2025, at the Austria Center Vienna, Austria.

1 · Reply

kevinmik Sep. 13 at 2:29 PM

$MNKD United Therapeutic has been working on building a new $500 million DPI manufacturing plant for Tyvaso since 2023 and I expect the facility is close to completion and eventual FDA approval. The question remains how will this new facility be utilized. United could decide to take over Tyvaso DPI from MNKD, shifting all manufacturing from Danbury to United new DPI plant. Depending on the timing of the move, I expect United would have to buyout and pay MNKD the remaining portion of their manufacturing/supply agreement that could be several $ millions, adding additional cash to MNKD balance sheet and elimiate the collaboration/service payment MNKD is receiving from United that is running $30 million quarterly. United taking over Tyvaso DPI manutacturing will free up Danbury to support MNKD's own manufacturing and supply needs and MNKD could end up repurchasing the Danbury building. Danbury would continue to support Tyvaso DPi as a backup supply source.

1 · Reply

oloccip__evets Sep. 13 at 1:44 PM

$MNKD It is the weekend..... I am with #TeamMike .........

0 · Reply

kevinmik Sep. 13 at 1:27 PM

$MNKD How much longer is MNKD going to run the business without a Chief Operating Officer and Chief Medical Officer ? These are two key leadership positions that are missing at MNKD and you have to wonder why. If MNKD is working on an exit strategy to sell the company, MNKD doesn't need a COO or CMO, but if the goal is to grow the company to become a top tiered biopharmaceutical company, MNKD needs to fill these positions. Hard to see MNKD continuing solely under the questionable leadership of Mike, who IMO at best should actually be a Chief Operating Officer overseeing day to day operations and have a new exciting experienced CEO in place to oversee the vision, branding and be the public face of MNKD. I don't believe Mike was responsible for MNKD shifting away from focusing solely on Afrezza and diabetes, adding R&D and rare diseases to the company's focus and he is just overseeing the changes that have likely come from the Board of Directors &/or other stake holders.

1 · Reply

MannKind Corporation (MNKD) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 7, 2025, 9:55 PM EDT - 6 days ago

MannKind Corporation (MNKD) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Sep 7, 2025, 9:28 PM EDT - 6 days ago

MannKind Corporation (MNKD) Presents At Cantor Global Healthcare Conference 2025 Transcript

Aug 27, 2025, 4:05 PM EDT - 17 days ago

MannKind to Present at Upcoming Investor Conferences

Aug 27, 2025, 8:05 AM EDT - 18 days ago

MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy

Aug 26, 2025, 5:58 PM EDT - 18 days ago

SCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPH

SCPH

Aug 25, 2025, 1:57 PM EDT - 19 days ago

MannKind, Backed By Blackstone, Expands Cardiorenal Focus With $360 Million Deal

Aug 25, 2025, 1:36 PM EDT - 19 days ago

MannKind Corporation (MNKD) Mergers and Acquisition Call Transcript

Aug 6, 2025, 5:20 PM EDT - 5 weeks ago

MannKind Corporation (MNKD) Q2 2025 Earnings Conference Call Transcript

Aug 6, 2025, 4:44 PM EDT - 5 weeks ago

MannKind Corporation: A Post-Q2 Assessment

Aug 6, 2025, 7:10 AM EDT - 5 weeks ago

MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement

Aug 6, 2025, 7:05 AM EDT - 5 weeks ago

MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update

Jul 30, 2025, 4:05 PM EDT - 6 weeks ago

MannKind Corporation to Hold 2025 Second Quarter Financial Results Conference Call on August 6, 2025

Jun 11, 2025, 7:01 AM EDT - 3 months ago

Top 3 Health Care Stocks That May Rocket Higher This Quarter

Jun 9, 2025, 4:05 PM EDT - 3 months ago

MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association's 85th Scientific Sessions in Chicago, June 20-23

May 27, 2025, 9:15 AM EDT - 3 months ago

INDYCAR Driver Conor Daly To Share His Personal Diabetes Story and Race Go-Karts With Detroit Area Youth On Thursday, May 29

May 27, 2025, 12:02 AM EDT - 3 months ago

MannKind: Why I'm Still Bullish Despite Tyvaso DPI Competition

May 8, 2025, 11:34 AM EDT - 4 months ago

MannKind Corporation (MNKD) Q1 2025 Earnings Call Transcript

May 8, 2025, 8:05 AM EDT - 4 months ago

MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update

May 1, 2025, 4:05 PM EDT - 4 months ago

MannKind Corporation to Hold 2025 First Quarter Financial Results Conference Call on May 8, 2025

Apr 7, 2025, 12:30 PM EDT - 5 months ago

MannKind Teams Up with Juncos Hollinger Racing (JHR) Driver Conor Daly to Drive Awareness of Diabetes and Innovative Treatment Options

Mar 10, 2025, 6:05 AM EDT - 6 months ago

MannKind Showcases Efficacy, Safety, and Mealtime Control Data from Recent Pediatric and Adult Studies of Afrezza® at the ATTD Conference, March 19-22

Feb 27, 2025, 10:32 AM EST - 7 months ago

MannKind Q4 Review: Solid Financials, But Tyvaso DPI's Market Share In Question

Feb 26, 2025, 9:09 PM EST - 7 months ago

MannKind Corporation (MNKD) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:05 PM EST - 7 months ago

MannKind Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 19, 2025, 4:05 PM EST - 7 months ago

MannKind Corporation to Hold 2024 Fourth Quarter and Full Year Financial Results Conference Call on February 26, 2025

Feb 3, 2025, 9:20 AM EST - 7 months ago

MoneyShow's Best Investment Ideas For 2025: Part 8

DELL FNV MSTR SKE SKYE AMSC

Jan 6, 2025, 4:30 PM EST - 8 months ago

MannKind Expands Executive Leadership Team

Dec 17, 2024, 7:16 AM EST - 9 months ago

MannKind Corporation: A Speculative Buy On IPF And Diabetes Markets

Dec 16, 2024, 6:05 AM EST - 9 months ago

MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)

Dec 11, 2024, 6:00 AM EST - 9 months ago

CDSCO Approves Afrezza® (insulin human) Inhalation Powder in India

Nov 7, 2024, 8:30 PM EST - 11 months ago

MannKind Corporation (MNKD) Q3 2024 Earnings Conference Call Transcript

Nov 7, 2024, 4:02 PM EST - 11 months ago

MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update

Nov 5, 2024, 4:15 PM EST - 11 months ago

MannKind to Present at 2024 UBS Healthcare Conference

Nov 4, 2024, 6:05 AM EST - 11 months ago

MannKind Successfully Completes Phase 1 Trial of Nintedanib DPI for Pulmonary Fibrotic Diseases

Oct 31, 2024, 4:05 PM EDT - 11 months ago

MannKind Corporation to Hold 2024 Third Quarter Financial Results Conference Call on November 7, 2024

Oct 30, 2024, 9:00 PM EDT - 11 months ago

First Site Initiated in Australia for MannKind's Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

Oct 3, 2024, 8:00 AM EDT - 1 year ago

MannKind Leverages Tyvaso DPI Strength In Pulmonary Market Expansion

Sep 30, 2024, 6:00 AM EDT - 1 year ago

More Adults With Type 1 Diabetes Achieved A1C Goal (

Sep 18, 2024, 6:15 AM EDT - 1 year ago

MannKind Announces Clearance from PMDA to Initiate Phase 3 Clinical Trial (ICoN-1) in Japan Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

Sep 10, 2024, 4:30 PM EDT - 1 year ago

MannKind to Present at 2024 Cantor Fitzgerald Global Healthcare Conference

Aug 27, 2024, 4:30 PM EDT - 1 year ago

MannKind to Present at Upcoming Conferences

Aug 14, 2024, 8:00 AM EDT - 1 year ago

Kent Kresa to Retire from MannKind's Board of Directors; Steven B. Binder to be Appointed to the Board

Aug 7, 2024, 12:29 PM EDT - 1 year ago

MannKind Corporation (MNKD) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 8:00 AM EDT - 1 year ago

MannKind Corporation Reports 2024 Second Quarter Financial Results: Provides Clinical Development Update

Jul 31, 2024, 6:30 AM EDT - 1 year ago

MannKind Launches Educational Website to Raise Awareness of NTM Lung Disease

Jul 30, 2024, 4:30 PM EDT - 1 year ago

MannKind Corporation to Hold 2024 Second Quarter Financial Results Conference Call on August 7, 2024

Jun 22, 2024, 8:00 AM EDT - 1 year ago

INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association's 84th Scientific Sessions

Jun 5, 2024, 6:45 AM EDT - 1 year ago

Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association's 84th Scientific Sessions

May 29, 2024, 8:45 AM EDT - 1 year ago

Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation

PULM

YolitheDolly Sep. 14 at 1:51 PM

0 · Reply

clan Sep. 14 at 10:15 AM

$MNKD I'm living rent-free in this habitual whiner's cavenous hollow head. MNKD-26In26

0 · Reply

Lazarus2024 Sep. 14 at 6:17 AM

2 · Reply

grampslol Sep. 13 at 5:01 PM

1 · Reply

grampslol Sep. 13 at 4:46 PM

$MNKD Reminder : Scripts for their only drug afrezza dpi approved in 2014 for diabetes were terrible for the week of 9/5/2025 ! Nrx 382 Rrx 471

0 · Reply

grampslol Sep. 13 at 4:42 PM

$MNKD I say No to presenting at EASD next week @kevinmik and Yes to the real possibility uthr will cut mnkd from the sma to save costs especially since lqda Yutrepria dpi is doing so well. JMHHO

0 · Reply

kevinmik Sep. 13 at 3:38 PM

1 · Reply

kevinmik Sep. 13 at 2:29 PM

1 · Reply

oloccip__evets Sep. 13 at 1:44 PM

$MNKD It is the weekend..... I am with #TeamMike .........

0 · Reply

kevinmik Sep. 13 at 1:27 PM

1 · Reply

grampslol Sep. 13 at 11:37 AM

$MNKD Sub $5 in '25 #afizzle

0 · Reply

clan Sep. 13 at 10:22 AM

$MNKD ~ Mannkind Happenings to come ~ ~ 2025: 🌶FDA accepts SNDA Furoscix autoinjector 🌶Oct. - scPharma merger closing 🌶Inhale-1 results 🌶Oct - Teton 2 encore update 🌶Afrezza applic. submission for pregs 🌶Oct - FDA approval Afrezza dosing label 🌶Nintedanib Ph 2 trial initiated (IPF) 🌶Clofazimine trial fully enrolled 🌶Nov ~5th ISPAD conf (kids Afrezza) 🌶Nov ~7th Earnings 3Q25 release w/ record Revs 🌶2nd $UTHR molecule announced 🌶FDA accepts peds sBLA 🌶Afrezza ships to India 🌶Expanded Afrezza Sales force & campaign 🌶MNKD > $10/sh ~ Early 2026 ~ 🧀Afrezza rollout India 🧀ICON-1 (clofaz.) update 🧀Feb ~26th - 4Q25 Earnings w/ record Revs 🧀US Afrezza TRx > 1K/wk 🧀Mar - ATTD conference 🧀Mar - Oppenheimer conf. 🧀Teton 1 (US) results 🧀INHALE AID Ex trial results 🧀Clofaz. (ICON-1) readout 🧀May ~12th Earnings 1Q26 w/ record Revs 🧀2Q26 FDA approval kids Afrezza 🧀FDA approve Furoscix autoinjector . . .

0 · Reply

grampslol Sep. 13 at 2:00 AM

$MNKD Anecdotes, fantasy and afizzle. #realitymatters

0 · Reply

NatesNotes Sep. 12 at 11:46 PM

$MNKD ...or... one could just do a little due diligence, Mr. Malarkey, and realize they'd been duped into publicly suggesting OTRK was a "bad call" on my part (as well as find out for themselves whether or not I still think it is a strong buy) #thedupedest ;-) #VdexandFriends #InTheirOwnWords #butmyfriendswroteitontheinterwebssoIassumeditwastrue #factsmatter

1 · Reply

nomalarkey Sep. 12 at 11:24 PM

$MNKD Should ask Nate if he still thinks OTRK is a strong buy.

0 · Reply

vly88 Sep. 12 at 10:43 PM

$MNKD @NatesNotes what do you think about ELTP?

1 · Reply

NatesNotes Sep. 12 at 10:17 PM

Sadly, as a number of the usual suspects on the $MNKD stream have shown us over the past few days, "A man hears what he wants to hear and disregards the rest..." ;-) #InTheirOwnWords #thedupedest #factsmatter

0 · Reply